Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30327314 | 0.99 | BTK (0.40) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL8325385 | 0.91 | BTK (0.43) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL21287424 | 0.90 | BTK (0.42) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL26969338 | 0.90 | BTK (0.42) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL8894795 | 0.88 | BTK (0.45) | BTKGAAEPHX2CTSKNFKB1 | |
| Hydrochloric Acid SCHEMBL25282690 | 0.86 | BTK (0.44) | BTKGAAEPHX2CTSKNFKB1 | |
| Oxalic Acid SCHEMBL30558780 | 0.84 | BTK (0.46) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL14669045 | 0.82 | BTK (0.49) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL14564127 | 0.82 | EPHX2 (0.42) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL24993887 | 0.82 | BTK (0.44) | BTKGAAEPHX2CTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601807-B | Exo-azaspiro inhibitors of MENIN-MLL interactions | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-26 | — | — | US | disclosed |
| US-20220204495-A1 | INHIBITING TRABID | Valo Health, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204495-A1 | INHIBITING TRABID | Valo Health, LLC | 2022-06-30 | — | — | US | disclosed |
| WO-2020227168-A1 | INHIBITING TRABID | INTEGRAL EARLY DISCOVERY, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | BTK 1/4885GAA 3319/4885EPHX2 1606/4885 |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | BTK 137/4885GAA 487/4885EPHX2 3880/4885 |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | BMI1, MLLT1, EED | BTK 3942/4885GAA 3576/4885EPHX2 2688/4885 |
| US-20220204495-A1 | INHIBITING TRABID | TPO, PRKACG, NFKBIA | BTK 2670/4885GAA 381/4885EPHX2 1364/4885 |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | BTK 1068/4885GAA 173/4885EPHX2 4197/4885 |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | BTK 3974/4885GAA 3501/4885EPHX2 2813/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | BTK 1/4885GAA 3319/4885EPHX2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.